Alveolar cleft osteoplasty using tissue-engineered osteogenic material.
H Hibi, Y Yamada, M Ueda...
https://pubmed.ncbi.nlm.nih.gov/16584868/Actively Recruiting
Led by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Updated on 2026-10-01
20
Participants Needed
1
Research Sites
34 weeks
Total Duration
Researchers are evaluating the safety and effectiveness of using autologous bone marrow-derived mononuclear cells BMMNCs combined with a bone graft material called Bio-Oss to repair severe bone defects in the maxillofacial jaw and alveolar area. This single-center, open-label study includes about 20 patients aged 18 to 60 years who have severe alveolar bone loss due to inflammation, trauma, or other causes. The trial aims to address the challenges of current bone grafting methods by using BMMNCs, which contain stem and progenitor cells that may help bone regeneration without needing laboratory expansion. Participants will undergo a procedure where approximately 60 mL of bone marrow is taken from their iliac crest. The BMMNCs are isolated on site using density-gradient centrifugation and mixed with Bio-Oss bone graft material. This mixture is then implanted into the bone defect and covered with a collagen membrane during surgery under local anesthesia. Routine antibiotics will be used around the time of the operation. Follow-up visits with imaging, including cone-beam CT scans, will be done immediately after surgery and at 3 and 6 months to measure new bone formation. If sufficient bone grows by 6 months, dental implants may be placed. Participants will be monitored through clinical examinations of the surgical site and laboratory tests such as blood counts, urinalysis, and liver and kidney function before surgery and during follow-ups at 1 week, 1 month, 3 months, and 6 months. Pain levels and any complications will also be recorded. The main outcome measured is the fraction of new bone volume in the grafted area. The total study duration for each participant is about 6 months, with safety and effectiveness tracked throughout this period.
CONDITIONS
Bone Marrow Mononuclear Cells for the Repair of Severe Maxillofacial Bone Defects
D
Dongyu Bao
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Single procedure with follow-up
Participants undergo surgery where their own bone marrow-derived mononuclear cells mixed with Bio-Oss bone graft material are implanted into the bone defect and covered with a collagen membrane.
Follow-up visits at 1 week, 1 month, 3 months, and 6 months after surgery
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
H Hibi, Y Yamada, M Ueda...
https://pubmed.ncbi.nlm.nih.gov/16584868/Erika Roddy, Malcolm R DeBaun, Adam Daoud-Gray...
https://pubmed.ncbi.nlm.nih.gov/29080923/Darnell Kaigler, Giorgio Pagni, Chan Ho Park...
https://pubmed.ncbi.nlm.nih.gov/22776413/The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Lead Sponsor